Forbes 30 Under 30 2020

From Forbes 30 Under 30 Profile:

With a background in life sciences technology development, unmet clinical needs discovery, and biotechnology entrepreneurship, Joshua Yang invents and commercializes biomedical technologies that he can translate into clinical practice. He also works to identify promising biotech and healthcare innovations and startups for investment opportunities. Yang co founded kidney diagnostics startup Nephrosant, which is based on his research into kidney injury prediction. The company is developing non-invasive tools to measure kidney injuries. Yang also is active in venture capital, performing due diligence and sourcing for Pear Ventures and SeaX ventures on healthcare deals.

Co-founder and CEO of Glyphic Biotechnologies, a VC-funded biotechnology startup commercializing a next-generation protein sequencing platform. My first startup Nephrosant has raised over $22M in funding to commercialize a low-cost, non-invasive diagnostic assay for kidney injury.

Double majored in Bioengineering: Biotechnology B.S. and General Biology B.S where I was a Barry Goldwater Scholar and the Valedictorian in Bioengineering. Subsequently, I completed a Master of Translational Medicine degree through the University of California, San Francisco and University of California, Berkeley in the Department of Bioengineering. I am currently on leave of absence from the MSTP MD-PhD at the Johns Hopkins University School of Medicine and Department of Biomedical Engineering. I graduated with an MBA from the Stanford University Graduate School of Business, where I was the Henry Ford II Scholar (Valedictorian), Siebel Scholar, and Arjay Miller Scholar.